Greetings Colleagues,

“Research cures cancer”.

Here at the University of Illinois Cancer Center we are keenly aware that advances in cancer research requires cooperation between patients, caregivers, and community leaders to bring us closer to a cure. We remain dedicated to providing promising new therapies for ALL patients.
Our investigators are continuously developing novel ways to prevent, diagnose, treat, manage, and cure cancer, as witnessed by our growing portfolio of clinical trials. As a provider in our referral network, you are a vital link in this partnership. This communication serves to inform you of our open clinical trials. We encourage you to contact our Cancer Clinical Trials Intake Coordinator at 312-355-5112 or if you identify a trial for which your patients may be eligible.  
We recognize that any relationship is built upon trust and ongoing communication. Please do not hesitate to contact us at or if you would like us to visit you at your practice location to discuss opportunities for further partnership. We look forward to serving your patients.

Yours truly,




Robert A. Winn, MD
Director, University of Illinois Cancer Center

Associate Vice Chancellor for Community Based Practice

John H. Stewart, IV, MD, MBA
Associate Director for Clinical Sciences

Physician Executive, Oncology Service Line












UI Cancer Center Investigator Initiated Clinical Trials


Below are unique UI Cancer Center clinical trials designed by our faculty which are currently enrolling patients (click on the study title for more info):

Breast Cancer
A Single Arm Phase II Study of Palbociclib in Combination with Tamoxifen as First Line Therapy for Metastatic Hormone Receptor Positive Breast Cancer (BTCRC-BRE15-016)
PI:  Oana Danciu, MD

Hematological Malignancies
A Phase II Study of Intensity Modulated Total Marrow Irradiation (TMI) in Addition to Fludarabine/ Busulfan Conditioning for Allogeneic Transplantation in High Risk AML and Myelodysplastic Syndromes (BMT-05)
PI:  Damiano Rondelli, MD

Lung Cancer
Phase II Study of Anti-PD-1 Antibody Pembrolizumab and Imprime PGG for Patients with Non-small Cell Lung Cancer Who Progressed after First Line Chemotherapy
PI:  Lawrence Feldman, MD

Solid Tumors
Phase I Study of PAC-1 in the Treatment of Advanced Hematologic Malignancy or Solid Tumors (STM-03)
PI:  Oana Danciu, MD



UI Cancer Center Clinical Trial Highlights


A Phase II Study of FOLFOX combined with Nab-Paclitaxel (FOLFOX-A) in the Treatment of Metastatic or Advanced Unresectable Gastric, Gastro-Esophageal Junction Adenocarcinoma (BTCRC-GI15-015)
PI: Rozina Chowdhery, MD

Head & Neck
Phase I Dose-Escalating Study of RiMO-301 with Radiation in Advanced Tumors (RiMO-CL17-001)
PI:  Lawrence Feldman, MD

Hematological Malignancies
A Phase I/II Study of Pomalidomide, Dexamethasone and Ixazomib Vs. Pomalidomide and Dexamethasone for Patients with Multiple Myeloma Refractory to Lenalidomide and Proteasome Inhibitor-Based Therapy (A061202)
PI:  Pritesh Patel, MD

Single Arm Phase Ib/II Study of Durvalumab and Guadecitabine in Advanced Kidney Cancer
PI:  David Peace, MD

A Phase II Trial of Chemotherapy plus Pembrolizumab in Patients with Advanced NSCLC Previously Treated With PD-1 or PD-L1 Inhibitor
PI:  Lawrence Feldman, MD




The University of Illinois Cancer Center is comprised of physicians and cancer researchers dedicated to pursuing health equity; working with the community in developing research and treatment options; and studying cancer disparities. We are part of the University of Illinois at Chicago and University of Illinois Hospital and Health Sciences System.


Contact us to find out more information or refer a patient.


Copyright © University of Illinois Cancer Center, All rights reserved.

Our mailing address is:
818 S Wolcott Ave. Chicago, IL 60612

Want to change how you receive these emails?
You unsubscribe from this list.